新規ドラッグデリバリーシステム市場：投与経路、モード、エンドユーザー別-2025-2030年の世界予測

新規ドラッグデリバリーシステム市場は、2023年に138億3,000万米ドルと評価され、2024年には150億米ドルに達すると予測され、CAGR 9.17%で成長し、2030年には255億7,000万米ドルに達すると予測されています。

調査手法（NDDS）は、医薬品化合物を制御された方法で送達し、治療成果を向上させるために設計された先進的な手法を包含します。NDDSは、薬物のバイオアベイラビリティ、標的特異性、投与回数の削減、副作用の最小化を高めるため、必要不可欠です。これらのシステムは、腫瘍学、神経学、慢性疾患など、正確なドラッグデリバリーが最重要とされる分野で大いに活用されています。最終用途の範囲には主に病院、診療所、調査機関が含まれ、革新的なドラッグデリバリー技術の熱心な消費者です。

主な市場促進要因としては、慢性疾患の増加、バイオテクノロジーの技術進歩、製薬企業による研究開発投資の増加などが挙げられます。高齢者人口の増加と効率的な疾病管理の必要性も市場成長を後押しします。現在のビジネスチャンスは、ナノテクノロジー応用、個別化医療、生分解性送達システム、経皮パッチや吸入器のような非侵襲的送達方法の開発にあります。こうした機会を活用するため、企業は共同研究、戦略的パートナーシップ、スマート・ドラッグ・デリバリー・システムのためのAIとIoTの統合に注力すべきです。

とはいえ、高い開発コスト、厳しい規制の枠組み、複雑な生物学的相互作用による潜在的な安全性の問題といった課題は依然として残っており、市場の成長を阻害する可能性があります。さらに、製薬会社はしばしば知的財産権の問題に直面し、技術革新や市場参入を阻害する可能性があります。研究開発費を合理化する一方で、規制に準拠した業務に注力することが極めて重要です。さらに、患者中心のデリバリー・システムの改良、新興市場への進出、アンメットニーズのある治療領域への取り組みが、イノベーションの最良の道となります。市場の競争は激しく、ダイナミックであるため、継続的なイノベーションと戦略的俊敏性が求められます。顧客中心のイノベーションを優先し、最先端の材料科学を活用することで、企業は最適な成長を達成し、市場との関連性を維持することができます。

市場力学：急速に進化する新規ドラッグデリバリーシステム市場の主要市場インサイトを解明

新規ドラッグデリバリーシステム市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の流行と老人人口の大幅な増加
  • 薬物放出制御技術の進歩
  • 新規ドラッグデリバリーシステムに関する政府の承認
• 市場抑制要因
  • 新規ドラッグデリバリーシステムに関連する既存の限界
• 市場機会
  • 新規ドラッグデリバリーシステム開発のための継続的進歩
  • 自己注射デバイスの採用増加
• 市場の課題
  • 治療薬や薬剤の送達に必要な合併症と専門知識

ポーターの5つの力：新規ドラッグデリバリーシステム市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：新規ドラッグデリバリーシステム市場における外部からの影響の把握

外部マクロ環境要因は、新規ドラッグデリバリーシステム市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析新規ドラッグデリバリーシステム市場における競合情勢の把握

新規ドラッグデリバリーシステム市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス新規ドラッグデリバリーシステム市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、新規ドラッグデリバリーシステム市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の蔓延と高齢者人口の大幅な増加
    • 薬物放出制御技術の進歩
    • 新規ドラッグデリバリーシステムの政府承認
  • 抑制要因
    • 新しいドラッグデリバリーシステムに関連する既存の制限
  • 機会
    • 新規ドラッグデリバリーシステムの開発の継続的な進歩
    • 自己注射デバイスの採用増加
  • 課題
    • 治療薬や薬剤の投与に必要な合併症と専門知識
• 市場セグメンテーション分析
  • 投与経路：慢性疾患管理における注射ドラッグデリバリーシステムの採用増加
  • エンドユーザー：予算の制約とより多くの患者に対応する必要性により、病院での新規ドラッグデリバリーシステムの使用が増加しています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 新規ドラッグデリバリーシステム市場：投与経路別

• 注射ドラッグデリバリーシステム
• 経口ドラッグデリバリーシステム
• 肺ドラッグデリバリーシステム
• 経皮ドラッグデリバリーシステム

第7章 新規ドラッグデリバリーシステム市場モード別

• 制御ドラッグデリバリーシステム
• 調節ドラッグデリバリーシステム
• 標的ドラッグデリバリーシステム

第8章 新規ドラッグデリバリーシステム市場：エンドユーザー別

• 病院
• 研究センター
• 専門クリニック

第9章 南北アメリカの新規ドラッグデリバリーシステム市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の新規ドラッグデリバリーシステム市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの新規ドラッグデリバリーシステム市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 新しいドラッグデリバリーのワンストップショップ
  • Viridian Therapeutics、ドラッグデリバリーの革新企業Enable Injectionsとの提携を発表
  • キンデバ・ドラッグデリバリーがサミット・バイオサイエンスを買収

企業一覧

• Novartis AG
• Societal CDMO
• Johnson & Johnson Services, Inc.
• AstraZeneca Plc
• Abbott Laboratories
• Sanofi S.A.
• Terumo Medical Corporation
• Pfizer Inc.
• Thermo Fisher Scientific Inc.
• Enable Injections, Inc.
• Pacira BioSciences, Inc.
• Bristol Myers Squibb Company
• Lonza Group Ltd.
• Spectrum Pharmaceuticals, Inc.
• Cospheric LLC
• Polysciences Inc.
• Insulet Corporation
• Bayer AG
• West Pharmaceutical Services, Inc.
• Mo-Sci Corporation
• Merck KGaA
• Boston Scientific Corporation
• Merit Medical Systems, Inc.
• GlaxoSmithKline PLC
• F. Hoffmann-La Roche Ltd.

LIST OF FIGURES

• FIGURE 1. NOVEL DRUG DELIVERY SYSTEMS MARKET RESEARCH PROCESS
• FIGURE 2. NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. NOVEL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. NOVEL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NOVEL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NOVEL DRUG DELIVERY SYSTEMS MARKET DYNAMICS
• TABLE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PULMONARY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CONTROLLED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODULATED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TARGETED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. CHINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. INDIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. ITALY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. POLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. QATAR NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. NOVEL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. NOVEL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2023

The Novel Drug Delivery Systems Market was valued at USD 13.83 billion in 2023, expected to reach USD 15.00 billion in 2024, and is projected to grow at a CAGR of 9.17%, to USD 25.57 billion by 2030.

The scope of Novel Drug Delivery Systems (NDDS) encompasses advanced methodologies designed to deliver pharmaceutical compounds in a controlled manner to achieve improved therapeutic outcomes. NDDS are essential because they enhance drug bioavailability, target specificity, reduce dosing frequency, and minimize side effects. These systems are highly applicable in areas such as oncology, neurology, and chronic conditions where precise drug delivery is paramount. The end-use scope primarily includes hospitals, clinics, and research institutes, which are avid consumers of innovative drug delivery technologies.

Key market drivers include the rising prevalence of chronic diseases, technological advancements in biotechnology, and increased R&D investments by pharmaceutical companies. The growing geriatric population and the need for efficient disease management also bolster market growth. Current opportunities lie in nanotechnology applications, personalized medicine, biodegradable delivery systems, and the development of non-invasive delivery methods like transdermal patches and inhalers. To capitalize on these opportunities, businesses should focus on collaborative research, strategic partnerships, and the integration of AI and IoT for smart drug delivery systems.

Nevertheless, challenges such as high development costs, stringent regulatory frameworks, and potential safety issues due to complex biological interactions persist, potentially impeding market growth. Moreover, pharmaceutical companies often face intellectual property rights issues, which can stall innovation and market entry. Rationalizing R&D expenditure while focusing on regulatory-compliant practices is crucial. Additionally, refining patient-centric delivery systems, expanding to emerging markets, and addressing therapeutic areas with unmet needs represent the best innovation avenues. The market's nature is highly competitive and dynamic, requiring continuous innovation and strategic agility. By prioritizing customer-centric innovation and leveraging cutting-edge materials science, companies can achieve optimal growth and maintain market relevance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Novel Drug Delivery Systems Market

The Novel Drug Delivery Systems Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of Chronic Diseases and Significant Rise in Geriatric Population
  • Advancements in Controlled Drug Release Technologies
  • Government Approvals for Novel Drug Delivery Systems
• Market Restraints
  • Existing Limitations Associated with Novel Drug Delivery System
• Market Opportunities
  • Ongoing Advancements for Development of Novel Drug Delivery Systems
  • Rising Adoption of Self-Injectable Devices
• Market Challenges
  • Complications and Expertise Required in Delivering Therapeutics and Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Novel Drug Delivery Systems Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Novel Drug Delivery Systems Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Novel Drug Delivery Systems Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Novel Drug Delivery Systems Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Novel Drug Delivery Systems Market

A detailed market share analysis in the Novel Drug Delivery Systems Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Novel Drug Delivery Systems Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Novel Drug Delivery Systems Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Novel Drug Delivery Systems Market, highlighting leading vendors and their innovative profiles. These include Novartis AG, Societal CDMO, Johnson & Johnson Services, Inc., AstraZeneca Plc, Abbott Laboratories, Sanofi S.A., Terumo Medical Corporation, Pfizer Inc., Thermo Fisher Scientific Inc., Enable Injections, Inc., Pacira BioSciences, Inc., Bristol Myers Squibb Company, Lonza Group Ltd., Spectrum Pharmaceuticals, Inc., Cospheric LLC, Polysciences Inc., Insulet Corporation, Bayer AG, West Pharmaceutical Services, Inc., Mo-Sci Corporation, Merck KGaA, Boston Scientific Corporation, Merit Medical Systems, Inc., GlaxoSmithKline PLC, and F. Hoffmann-La Roche Ltd..

Market Segmentation & Coverage

This research report categorizes the Novel Drug Delivery Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Route of Administration, market is studied across Injectable Drug Delivery Systems, Oral Drug Delivery Systems, Pulmonary Drug Delivery Systems, and Transdermal Drug Delivery Systems.
• Based on Mode, market is studied across Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Targeted Drug Delivery Systems.
• Based on End-User, market is studied across Hospital, Research Centers, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of Chronic Diseases and Significant Rise in Geriatric Population
    • 5.1.1.2. Advancements in Controlled Drug Release Technologies
    • 5.1.1.3. Government Approvals for Novel Drug Delivery Systems
  • 5.1.2. Restraints
    • 5.1.2.1. Existing Limitations Associated with Novel Drug Delivery System
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing Advancements for Development of Novel Drug Delivery Systems
    • 5.1.3.2. Rising Adoption of Self-Injectable Devices
  • 5.1.4. Challenges
    • 5.1.4.1. Complications and Expertise Required in Delivering Therapeutics and Drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Route of Administration: Rising adoption of injectable drug delivery systems for chronic disease management
  • 5.2.2. End-User: Increasing use of novel drug delivery systems in the hospital due to budget constraints and the necessity to cater to a larger patient base
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Novel Drug Delivery Systems Market, by Route of Administration

• 6.1. Introduction
• 6.2. Injectable Drug Delivery Systems
• 6.3. Oral Drug Delivery Systems
• 6.4. Pulmonary Drug Delivery Systems
• 6.5. Transdermal Drug Delivery Systems

7. Novel Drug Delivery Systems Market, by Mode

• 7.1. Introduction
• 7.2. Controlled Drug Delivery Systems
• 7.3. Modulated Drug Delivery Systems
• 7.4. Targeted Drug Delivery Systems

8. Novel Drug Delivery Systems Market, by End-User

• 8.1. Introduction
• 8.2. Hospital
• 8.3. Research Centers
• 8.4. Specialty Clinics

9. Americas Novel Drug Delivery Systems Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Novel Drug Delivery Systems Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Novel Drug Delivery Systems Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Novel drug delivery one-stop shop
  • 12.3.2. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
  • 12.3.3. Kindeva Drug Delivery acquires Summit Biosciences

Companies Mentioned

• 1. Novartis AG
• 2. Societal CDMO
• 3. Johnson & Johnson Services, Inc.
• 4. AstraZeneca Plc
• 5. Abbott Laboratories
• 6. Sanofi S.A.
• 7. Terumo Medical Corporation
• 8. Pfizer Inc.
• 9. Thermo Fisher Scientific Inc.
• 10. Enable Injections, Inc.
• 11. Pacira BioSciences, Inc.
• 12. Bristol Myers Squibb Company
• 13. Lonza Group Ltd.
• 14. Spectrum Pharmaceuticals, Inc.
• 15. Cospheric LLC
• 16. Polysciences Inc.
• 17. Insulet Corporation
• 18. Bayer AG
• 19. West Pharmaceutical Services, Inc.
• 20. Mo-Sci Corporation
• 21. Merck KGaA
• 22. Boston Scientific Corporation
• 23. Merit Medical Systems, Inc.
• 24. GlaxoSmithKline PLC
• 25. F. Hoffmann-La Roche Ltd.